The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class i histone deacetylases

Journal of Biological Chemistry

Volumn 288, Issue 35, 2013, Pages 25593-25602

  Kikuchi, Jiro ^a   Yamada, Satoshi ^a   Koyama, Daisuke ^a   Wada, Taeko ^a   Nobuyoshi, Masaharu ^a   Izumi, Tohru ^b   Akutsu, Miyuki ^b   Kano, Yasuhiko ^b   Furukawa, Yusuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOCHIGI CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLASS I; HISTONE DEACETYLASES; IN-VITRO; MECHANISM OF ACTION; ORALLY ACTIVE; PROTEASOME INHIBITORS; PROTEASOMES; TRANSCRIPTIONAL REPRESSION;

BIOCHEMISTRY;

BIOLOGY;

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 8; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; K 7174; MELPHALAN; N,N BIS[5 (3,4,5 TRIMETHOXYPHENYL) 4 PENTENYL]HOMOPIPERAZINE; PERFOSFAMIDE; PROTEASOME; ROMIDEPSIN; TRANSCRIPTION FACTOR SP1; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; LIVER DYSFUNCTION; MELANOMA; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; ONCOGENE; ONCOGENE CLASS I HDAC; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; TOXICITY TESTING; TRANSCRIPTION REGULATION; TUMOR VOLUME; WEIGHT REDUCTION;

CANCER; DRUG RESISTANCE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITORS; MULTIPLE MYELOMA; PROTEASOME;

ADMINISTRATION, ORAL; ANIMALS; ANISOLES; ANTINEOPLASTIC AGENTS; AZEPINES; BORONIC ACIDS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; PYRAZINES;

EID: 84883317822     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.480574     Document Type: Article

References (44)

1. Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., and Harousseau, J. L. (2012) Proteasome inhibitors in multiple myeloma. 10 years later. Blood 120, 947-959
2. Friedberg, J. W., Vose, J. M., Kelly, J. L., Young F., Bernstein, S. H., Peterson, D., Rich, L., Blumel, S., Proia, N. K., Liesveld, J., Fisher, R. I., Armitage, J. O., Grant, S., and Leonard, J. P. (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117, 2807-2812
3. San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., Dmoszynska, A., Abdulkadyrov, K. M., Delforge, M., Jiang, B., Mateos, M. V., Anderson, K. C., Esseltine, D. L., Liu, K., Deraedt, W., Cakana, A., van de Velde, H., and Richardson, P. G. (2013) Persistent overall survival benefit and no increased risk of second malignancies with bortezomib- melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J. Clin. Oncol. 31, 448-455
4. Lonial, S., Waller, E. K., Richardson, P. G., Jagannath, S., Orlowski, R. Z., Giver, C. R., Jaye, D. L., Francis, D., Giusti, S., Torre, C., Barlogie, B., Berenson, J. R., Singhal, S., Schenkein, D. P., Esseltine, D. L., Anderson, J., Xiao, H., Heffner, L. T., and Anderson, K. C., SUMMIT/CREST Investigators. (2005) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106, 3777-3784
5. Richardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D. S., Irwin, D., Schuster, M., Srkalovic, G., Alexanian, R., Rajkumar, S. V., Limentani, S., Alsina, M., Orlowski, R. Z., Najarian, K., Esseltine, D., Anderson, K. C., and Amato, A. A. (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol. 24, 3113-3120
6. Hideshima, T., and Anderson, K. C. (2011) Novel therapies in MM. From the aspect of preclinical studies. Int. J. Hematol. 94, 344-354
7. Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W., Chanan-Khan, A. A., and Orlowski, R. Z. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110, 3281-3290
8. Khan, M. L, and Stewart, A. K. (2011) Carfilzomib. A novel second-generation proteasome inhibitor. Future Oncol. 7, 607-612
9. Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., Ovaa, H., Berkers, C., Nicholson, B., Chao, T. H., Neuteboom, S. T., Richardson, P., Palladino, M. A., and Anderson, K. C. (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8, 407-419
10. Piva, R., Ruggeri, B., Williams, M., Costa, G., Tamagno, I., Ferrero, D., Giai, V., Coscia, M., Peola, S., Massaia, M., Pezzoni, G., Allievi, C., Pescalli, N., Cassin, M., di Giovine, S., Nicoli, P., de Feudis, P., Strepponi, I., Roato, I., Ferracini, R., Bussolati, B., Camussi, G., Jones-Bolin, S., Hunter, K., Zhao, H., Neri, A., Palumbo, A., Berkers, C., Ovaa, H., Bernareggi, A., and Inghirami, G. (2008) CEP-18770. A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111, 2765-2775
11. Kupperman, E., Lee, E. C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., Yu, J., Yang, Y., Hales, P., Bruzzese, F., Liu, J., Blank, J., Garcia, K., Tsu, C., Dick, L., Fleming, P., Yu, L., Manfredi, M., Rolfe, M., and Bolen, J. (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70, 1970-1980
12. Chauhan, D., Singh, A. V., Aujay, M., Kirk, C. J., Bandi, M., Ciccarelli, B., Raje, N., Richardson, P., and Anderson, K. C. (2010) A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116, 4906-4915
13. Lü, S., Yang, J., Song, X., Gong, S., Zhou, H., Guo, L., Song, N., Bao, X., Chen, P., and Wang, J. (2008) Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib- selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J. Pharmacol. Exp. Ther. 326, 423-431
14. Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., van der Heijden, J. W., Ylstra, B., Peters, G. J., Kaspers, G. L., Dijkmans, B. A., Scheper, R. J., and Jansen, G. (2008) Molecular basis of bortezomib resistance. Proteasome subunit β5 (PSMB5) gene mutation and over-expression of PSMB5 protein. Blood 112, 2489-2499
15. Franke, N. E., Niewerth, D., Assaraf, Y. G., van Meerloo, J., Vojtekova, K., van Zantwijk, C. H., Zweegman, S., Chan, E. T., Kirk, C. J., Geerke, D. P., Schimmer, A. D., Kaspers, G. J., Jansen, G., and Cloos, J. (2012) Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 26, 757-768
16. Umetani, M., Nakao, H., Doi, T., Iwasaki, A., Ohtaka, M., Nagoya, T., Mataki, C., Hamakubo, T., and Kodama, T. (2000) A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA. Biochem. Biophys. Res. Commun. 272, 370-374
17. Imagawa, S., Nakano, Y., Obara, N., Suzuki, N., Doi, T., Kodama, T., Nagasawa, T., and Yamamoto, M. (2003) A GATA-specific inhibitor (K- 7174) rescues anemia induced by IL-1β, TNF-α, or L-NMMA. FASEB J. 17, 1742-1744
18. Kikuchi, J., Shibayama, N., Yamada, S., Wada, T., Nobuyoshi, M., Izumi, T., Akutsu, M., Kano, Y., Sugiyama, K., Ohki, M., Park, S-Y., Furukawa, Y. (2013) Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding, PLoS One 8, e60649
19. Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., Adams, J., and Anderson, K. C. (2002) NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem. 277, 16639-16647
20. Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N. C., Richardson, P. G., Carrasco, R. D., and Anderson, K. C. (2009) Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells. Blood 114, 1046-1052
21. Kikuchi, J., Wada, T., Shimizu, R., Izumi, T., Akutsu, M., Mitsunaga, K., Noborio-Hatano, K., Nobuyoshi, M., Ozawa, K., Kano, Y., and Furukawa, Y. (2010) Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 116, 406-417
22. Drexler, H. G., Matsuo, Y., and MacLeod, R. A. (2003) Persistent use of false myeloma cell lines. Hum. Cell 16, 101-105
23. Shimizu, R., Kikuchi, J., Wada, T., Ozawa, K., Kano, Y., and Furukawa, Y. (2010) HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 24, 1760-1768
24. Noborio-Hatano, K., Kikuchi, J., Takatoku, M., Shimizu, R., Wada, T., Ueda, M., Nobuyoshi, M., Oh, I., Sato, K., Suzuki, T., Ozaki, K., Mori, M., Nagai, T., Muroi, K., Kano, Y., Furukawa, Y., and Ozawa, K. (2009) Bortezomib overcomes cell-adhesion-mediated drug resistance through down-regulation of VLA-4 expression in multiple myeloma. Oncogene. 28, 231-242
25. Ri, M., Iida, S., Nakashima, T., Miyazaki, H., Mori, F., Ito, A., Inagaki, A., Kusumoto, S., Ishida, T., Komatsu, H., Shiotsu, Y., and Ueda, R. (2010) Bortezomib-resistant myeloma cell lines. A role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24, 1506-1512
26. Kikuchi, J., Shimizu, R., Wada, T., Ando, H., Nakamura, M., Ozawa, K., and Furukawa, Y. (2007) E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1. Stem Cells 25, 2439-2447
27. Nonomura, C., Kikuchi, J., Kiyokawa, N., Ozaki, H., Mitsunaga, K., Ando, H., Kanamori, A., Kannagi, R., Fujimoto, J., Muroi, K., Furukawa, Y., and Nakamura M. (2008) CD43, but not P-selectin glycoprotein ligand-1, functions as an E-selectin counter-receptor in human B cell precursor leukemia NALL-1. Cancer Res. 68, 790-799
28. Wada, T., Kikuchi, J., Nishimura, N., Shimizu, R., Kitamura, T., and Furukawa, Y. (2009) Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J. Biol. Chem. 284, 30673-30683
29. Fulciniti, M., Amin, S., Nanjappa, P., Rodig, S., Prabhala, R., Li, C., Minvielle, S., Tai, Y. T., Tassone, P., Avet-Loiseau, H., Hideshima, T., Anderson, K. C., and Munshi, N. C. (2011) Significant biological role of Sp1 transactivation in multiple myeloma. Clin. Cancer Res. 17, 6500-6509
30. Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington, W. J., Jr., Lee, K. P., and Boise, L. H. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907-4916
31. Mannava, S., Zhuang, D., Nair, J. R., Bansal, R., Wawrzyniak, J. A., Zucker, S.N., Fink, E.E., Moparthy, K. C., Hu, Q., Liu, S., Boise, L. H., Lee, K. P., and Nikiforov, M. A. (2012) KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 119, 1450-1458
32. Miller, C. P., Rudra, S., Keating, M. J., Wierda, W. G., Palladino, M., and Chandra, J. (2009) Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052. A mechanism for synergy in leukemia cells. Blood 113, 4289-4299
33. Richardson, P., Mitsiades, C., Colson, K., Reilly, E., McBride, L., Chiao, J., Sun, L., Ricker, J., Rizvi, S., Oerth, C., Atkins, B., Fearen, I., Anderson, K., and Siegel, D. (2008) Phase 1 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma. 49, 502-507
34. Niesvizky, R., Ely, S., Mark, T., Aggarwal, S., Gabrilove, J. L., Wright, J. J., Chen-Kiang, S., and Sparano, J. A. (2011) Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117, 336-342
35. Wada, T., Kikuchi, J., and Furukawa, Y. (2012) Histone deacetylase 1 enhances microRNA processing via deactylation of DGCR8. EMBO Rep. 13, 142-149
36. Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J. L., Bonine-Summers, A. R., Wells, C. E., Kaiser, J. F., Washington, M. K., Zhao, Z., Wagner, F. F., Sun, Z. W., Xia, F., Holson, E. B., Khabele, D., and Hiebert, S. W. (2010) Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 18, 436-447
37. Delcuve, G. P., Khan, D. H., and Davie, J. R. (2013) Targeting class I histone deacetylases in cancer therapy. Expert. Opin. Ther. Targets 17, 29-41
38. Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., Wong, K. K., Brandstetter, K., Wittner, B., Ramaswamy, S., Classon, M., and Settleman, J. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80
39. Zhang, B., Strauss, A. C., Chu, S., Li, M., Ho, Y., Shiang, K. D., Snyder, D. S., Huettner, C. S., Shultz, L., Holyoake, T., and Bhatia, R. (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17, 427-442
40. Chesi, M., Matthews, G. M., Garbitt, V. M., Palmer, S. E., Shortt, J., Lefebure, M., Stewart, A. K., Johnstone, R. W., and Bergsagel, P. L. (2012) Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120, 376-385
41. Harrison, S. J., Quach, H., Link, E., Seymour, J. F., Ritchie, D. S., Ruell, S., Dean, J., Januszewicz, H., Johnstone, R., Neeson, P., Dickinson, M., Nichols, J., and Prince, H. M. (2011) A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 118, 6274-6283
42. Knop, S. (2011) From the observation DAC. Romidepsin revisited. Blood 118, 6231-6232
43. McConkey, D. (2010) Proteasome and HDAC. Who's zooming who Blood 116, 308-309
44. Chou, T-C. (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440-446